https://www.selleckchem.com/pr....oducts/trastuzumab-e
Importantly, the insights gained from these biomarker studies can guide rational combinatorial strategies such as CDK4/6 inhibitor/fractionated radiotherapy/HDACi in conjunction with ICBs to maximize therapeutic benefits. Further, with the rapid technological advents (e.g., ATCT-Seq), we predict more reliable biomarkers will be identified, which in turn will inspire more promising combination therapies.After more than one hundred years of documented trials, immunotherapy has become a standard of care in the treatmen
Like
Comment
Share
